Baheal Wisart focuses on cutting-edge technologies transformation and innovative medicines R&D of the cardiovascular diseases. It possesses internationally leading technologies for the preservation, isolation, cultivation and cryopreservation of human primary cardiomyocytes. Based on State Key Laboratory of Cardiovascular Disease, Baheal Wisart is fully committed to the R&D and translation of cardiovascular diseases innovative medicines, effectively serving the national strategic needs for the prevention and treatment of cardiovascular diseases.

Based on State Key Laboratory of Cardiovascular Disease, Baheal Guoxin is committed to the R&D of breakthrough technologies and achievement transformation platform for Cardiovascular Medical Devices. With the non-invasive radiotherapy system for arrhythmia as its core breakthrough, the enterprise innovatively integrates radiotherapy with cardiac electrophysiology to transform its treatment methods from invasive surgery to precise and non-invasive therapies, to drive a technological revolution in cardiovascular diseases treatment.

Committed to the mission of "Better Science, Better Home Health", Baheal Home serves as a professional platform for home health management, leveraging health assessments, data tracking, and online health services to provide tailored and accurate health management solutions for a diverse consumer base.

Founded in 2008, BRIOHEALTH TECHNOLOGIES is dedicated to independently conducting the research, development, manufacturing and commercialization of the world’s state-of-the-art ventricular assist device (VAD). Through continuously providing exceptional service to medical professionals and patients, this product could help a wider range of heart failure patients and their families to live better lives. With the technological accumulation in the field of fully magnetically levitated VAD, CH Biomedical has developed Cifu® VAD, the first fully magnetically levitated VAD to be approved in China. It has established comprehensive patent portfolio, and got listed in the “2021 China Annual Medical Achievements” reports. In light of the latest breakthroughs in key clinical performance of its product, BRIOHEALTH TECHNOLOGIES is recognized as technology innovator among international VAD community. BRIOHEALTH SOLUTIONS is committed to promoting continuous innovation in the VAD industry by forging resource collaborations on a global scale, and it is becoming a next generation leader in the global VAD industry.

Huake Pioneer focuses on providing radiation therapy solutions for patients with whole-body tumors and arrhythmias with the top-tier medical linear accelerators. Based on the global leading 4π radiotherapy technology, the company is guided by clinical requirements to develop world-class medical linear accelerators and associated software for the treatment of cancer and various illnesses.

RabPharma is a pioneering research and development platform in the medical sector, focusing on challenging orthopedic conditions. Motivated by the unmet medical needs both in China and globally, the company is developing original therapeutics with first-in-class or best-in-class potential.

JI LUN TAI is committed to providing comprehensive solutions for nuclear medicine molecular imaging diagnosis and treatment. We focus on the research and development of top-level radioactive drugs with independent intellectual property rights in global scale, driving equipment innovation along with drug innovation. Our pipeline covers multiple fields including SPECT diagnostic medicines, PET diagnostic medicines, targeted therapeutic drugs and imaging equipment.

SicaGene is a pioneering pharmaceutical company dedicated to the research and development of next-generation antisense oligonucleotide (ASO) therapeutics. Leveraging a state-of-the-art ASO drug innovation and research platform, the company enables precise regulation of target proteins, facilitates efficient ASO drug target screening, and streamlines the ASO drug development process by reducing both complexity and cost. Currently, SicaGene has multiple compounds have entered the clinical research stage. As a result, this company has been honored as a "National High-Tech Enterprise" and "Specialized and Sophisticated SMEs”.

Cailusly develops Multi-Organ-On-a-Chip micro physiological system towards personalized precision medicine. It provides a dynamic, replicable in vitro miniaturized model of human organ system that serves as research platform for the study of disease mechanisms, biological targets, and developing targeted therapeutic drugs.

Baheal Glycomtech focuses on the research of polysaccharides, glyco-proteome, and glyco-transcriptome. It is dedicated to discovering key targets and biomarkers associated with major diseases such as malignant tumors, cardiovascular diseases, autoimmune diseases, and neurodegenerative diseases.

Taking the “14th Five Year Plan” national key research and development project, photon counting energy spectral CT, as an opportunity, Beijing Photon Counting Medical Technology Ltd. focuses on the development and commercialization of single source and multi-source photon counting CT systems, and is dedicated to becoming an industry innovator and technology pioneer. It has developed the CT detector ASIC chip with full IP, achieved its mass production and owned all technologies including key components, core algorithms, sub-system and system design.